aap Implantate AG
aap Implantate AG: Supervisory Board extends both Management Board members’ contracts prematurely until the end of 2020
DGAP-News: aap Implantate AG / Key word(s): Change of Personnel/Miscellaneous aap Implantate AG (“aap“) announces that the Supervisory Board decided today to extend the contracts of Management Board Chairman Bruke Seyoum Alemu (CEO) and Chief Financial Officer Marek Hahn (CFO) prematurely for a further three years until the end of 2020. Bruke Seyoum Alemu (52) has served aap in various top management positions for many years and has been the Chairman of the Management Board (CEO) since June 2014. He is responsible for Corporate Development, Research & Development, Production, Quality Assurance and Control, Regulatory Affairs as well as Sales and Marketing. Marek Hahn (42) has been a member of the Management Board (CFO) at aap since April 2010. In his role as Chief Financial Officer he is responsible in the company for Finance/ Controlling, Human Resources, IT, Legal Affairs, Investor and Public Relations as well as Administration. “By extending the contracts with Mr. Alemu and Mr. Hahn we focus on continuity at the top management level in the years ahead as well,” says Biense Visser, Chairman of the Supervisory Board at aap. “In recent years Mr. Alemu and Mr. Hahn have consistently and successfully undertaken the transformation of aap from a diversified medical technology company into a pure player in trauma. The company now has a comprehensive IP-protected product and technology portfolio as well as a strong liquidity position and can take even better advantage of the opportunities in the growing trauma market with its focused business model. Management Board and Supervisory Board must now continue to consequently implement the strategy in order to unlock the inherent value of our innovative product and technology base and thereby create sustainable value for aap’s shareholders.” _______________________________________________________________________________________ aap Implantate AG (ISIN DE0005066609) – Prime Standard/Regulated Market – All German stock markets – Contact: aap Implantate AG; Fabian Franke; Investor Relations; Lorenzweg 5; D-12099 Berlin Tel.: ++49/30/750 19 – 134; Fax.: ++49/30/750 19 – 290; f.franke@aap.de
15.06.2017 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |
Language: | English |
Company: | aap Implantate AG |
Lorenzweg 5 | |
12099 Berlin | |
Germany | |
Phone: | +49 (0) 30 75 01 90 |
Fax: | +49 (0) 30 75 01 91 11 |
E-mail: | info@aap.de |
Internet: | www.aap.de |
ISIN: | DE0005066609 |
WKN: | 506660 |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
End of News | DGAP News Service |